<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34417339</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS.</ArticleTitle><Pagination><StartPage>68</StartPage><EndPage>74</EndPage><MedlinePgn>68-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2021-327129</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Elevated levels of neurofilament light (NfL) and heavy (NfH) chain in amyotrophic lateral sclerosis (ALS) cerebrospinal fluid (CSF) and serum reflect neuro-axonal degeneration and are used as diagnostic biomarkers. However, studies comparing the differential diagnostic potential for ALS of all four parameters are missing. Here, we measured serum NfL/NfH and CSF NfL/NfH in a large cohort of ALS and other neurological disorders and analysed the differential diagnostic potential.</AbstractText><AbstractText Label="METHODS">In total CSF and serum of 294 patients were analysed. The diagnostic groups comprised: ALS (n=75), frontotemporal lobar degeneration (FTLD) (n=33), Alzheimer's disease (n=20), Parkinson's disease (dementia) (n=18), Creutzfeldt-Jakob disease (n=11), non-neurodegenerative controls (n=77) (Con) and 60 patients who were seen under the direct differential diagnosis of a patient with ALS (Con.DD).</AbstractText><AbstractText Label="RESULTS">CSF and serum NfL and NfH showed significantly increased levels in ALS (p&lt;0.0001) compared with Con and Con.DD. The difference between ALS and FTLD was markedly stronger for NfH than for NfL. CSF and serum NfL demonstrated a stronger correlation (r=0.84 (95% CI 0.80 to 0.87), p&lt;0.001) than CSF and serum NfH (r=0.68 (95% CI 0.61 to 0.75), p&lt;0.0001). Comparing ALS and Con.DD, receiver operating characteristic analysis revealed the best area under the curve (AUC) value for CSF NfL (AUC=0.94, 95%&#x2009;CI 0.91 to 0.98), followed by CSF NfH (0.93, 95% CI 0.88 to 0.98), serum NfL (0.93, 95% CI 0.89 to 0.97) and serum NfH (0.88, 95% CI 0.82 to 0.94).</AbstractText><AbstractText Label="CONCLUSION">Our results demonstrate that CSF NfL and NfH as well as serum NfL are equally suited for the differential diagnosis of ALS, whereas serum NfH appears to be slightly less potent.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Halbgebauer</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinacker</LastName><ForeName>Petra</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-6697-6522</Identifier><AffiliationInfo><Affiliation>Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verde</LastName><ForeName>Federico</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-3977-6995</Identifier><AffiliationInfo><Affiliation>Department of Neurology - Stroke Unit and Laboratory of Neuroscience, Istituto Auxologico Italiano Istituto di Ricovero e Cura a Carattere Scientifico, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, Universit&#xe0; degli Studi di Milano, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weishaupt</LastName><ForeName>Jochen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Institute for Neurodegeneration, Universit&#xe4;tsmedizin Mannheim, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oeckl</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7652-7023</Identifier><AffiliationInfo><Affiliation>Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen (DZNE e.V.), Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Arnim</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, University Medical Center, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorst</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feneberg</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Rechts der Isar, Munich, Bayern, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute for Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenbohm</LastName><ForeName>Angela</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9700-0338</Identifier><AffiliationInfo><Affiliation>Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silani</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology - Stroke Unit and Laboratory of Neuroscience, Istituto Auxologico Italiano Istituto di Ricovero e Cura a Carattere Scientifico, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, Universit&#xe0; degli Studi di Milano, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Markus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6647-5944</Identifier><AffiliationInfo><Affiliation>Neurology, University of Ulm, Ulm, Germany markus.otto@uk-halle.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University clinic, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: SH, PS, FV, JW, PO, JD, EF, BM, AR, VS and ACL report no competing interests. CVA received honoraria from serving on the scientific advisory board of Biogen, Roche, and Willmar Schwabe &amp; Co. KG and has received funding for travel and speaker honoraria from Lilly GmbH, Daiichi Sankyo, Biogen, Roche diagnostics AG and Willmar Schwabe GmbH &amp;Co. KG and has received research support from Roche diagnostics AG. MO gave scientific advice for Fujirebio, Roche, Biogen and Axon.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>21</Day><Hour>5</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34417339</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2021-327129</ArticleId><ArticleId IdType="pii">jnnp-2021-327129</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>